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Introduction
Barbiturate is a therapeutic option for the treatment of
elevated intracranial pressure (eICP) in Traumatic brain
injury (TBI) patients. It is used in 20% of the patients in a
recent European cohort [1]. But, barbiturate may induce
an immunosuppression. Indeed, barbiturate have been
shown to induce a decrease in white blood cells in old
reports [2] and to be associated to early ventilator asso-
ciated pneumonia (VAP) [3]).
Objectives
To assess if barbiturate is a risk factor for VAP in TBI
patients.
Methods
We conducted a post-hoc analysis of data obtained from 2
RCTs (Corti-TC and SPIRIT), in which use of barbiturate
was prospectively collected. Occurrence of VAP, microbio-
logically confirmed, was the primary endpoint of these 2
RCTs. We conduct an univariate and multivariate analysis
to identify risk factors associated with onset of early (≤7
days) or late (>7 days) VAP. Data are expressed as mean ±
SD, medians (Q1-Q3) or Odd Ratio with (95% Confident
Intervals).
Results
Among the 441 severe TBI patients (age 39 ± 17 yrs, 135
(80.3%) Male, SAPS II 44.7 ± 11.3, initial Glasgow score
5.7 ± 1.9, ISS 20.5 ± 13.7) included in the 2 RCTs (n = 275
for corti-TC and 166 for Spirit), 183(41%) experienced at
least one episode of eICP (ICP>20 mmHg). Among these
183 patients, 138(75%) were treated with barbiturate
(1[0-2] days after admission, for a duration of 3 (1-6) days
in Corti-TC study). Characteristics of patients with eICP
treated with barbiturate or not were not different, except
for hyperventilation more often used in barbiturate
patients (16(12%) vs 0 times, p = 0.017). In logistic regres-
sion, barbiturate use was the only factor associated with
early VAP (OR 5.56 (95CI; 1.44-21.44), p = 0.013). The
other factors included in the analysis were: gender, use of
decompressive craniectomy, SAPS II score, initial Glasgow
score, Head AIS Score, Tabaco use). This association with
barbiturate use was not found for late onset VAP (OR 0.48
(0.17-1.39), p = 0.18). Only the initial head AIS score was
associated with late VAP (OR 1.19 (1.21-3.02), p = 0.005).
Patients treated with barbiturate had less ventilator free
days at D28 (7 ± 8 days compared to 12 ± 9 for patients
with eICP, p = 0.001, and to 13 ± 8 for the entire popula-
tion, p = 0.001). Survival rate at day 28 was not different
in barbiturate treated patients (71(60%) vs 14(64%)
patients alive at D28, p = 0.72).
Discussion
In these 2 recent RCTs, barbiturate use was an indepen-
dent predictive factor for early VAP. This could be linked
to the severity of the patients (despite the adjustments
done. The absence of association with late pneumonia
does not support a prolonged barbiturate induced immu-
nosuppression. The ongoing longitudinal analysis, taking
into account the time factor, will probably help to precise
if barbiturate is a risk factor for early VAP or not.
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